Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease

Clinical Nephrology

Volumn 63, Issue 5, 2005, Pages 327-334

  Ling, B ^a   Walczyk, M ^b   Agarwal, A ^c   Carroll, W ^d   Liu, W ^d   Brenner, R ^d  

^a Mountain Kidney Associates   (United States)

^b Northwest Renal Clinic   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d AMGEN INC   (United States)

Author keywords

Anemia; Chronic renal insufficiency; Drug therapy; Glycoprotein; Safety

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA MULTIFORME; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL EDEMA; RESPIRATORY FAILURE; UPPER RESPIRATORY TRACT INFECTION;

EID: 18744363354     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP63327     Document Type: Article

References (31)

1. Barrett BJ, Parfrey PS, Morgan J et al 1997 Prediction of early death in end-stage renal disease patients starting dialysis. Am J Kidney Dis 29: 214-222
2. Besarab A, Levin A 2000 Defining a renal anemia management period. Am J Kidney Dis 36: S13-23
3. Cockroft DW, Gault MH 1976 Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
4. Coresh J, Astor BC, Greene T, Eknoyan G, Levey A 2063 Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutritional Survey. Am J Kidney Dis 41: 1-12
5. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D 1999 Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56: 22142-22149
6. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos M 2003 Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31: 290-299
7. Fink J. Blahut S, Reddy M, Light P 2001 Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37: 348-355
8. Foley RN, Parfrey PS, Harnett JD et al 1995 Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192
9. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE 1996 The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61
10. Germain M, Ram CV, Bhaduri S, Tang KL, Klausner M, Curzi M 2003 Retrospective review of extended epoetin alfa dosing in patients with anemia of chronic kidney disease (CKD): final results of the RAPID study. Am Soc Nephrol, November 12-17, San Diego, CA 2003, Abstract PUB 169
11. Gilbertson T, Shuling L, Murray A, Herzog, C, Collins A 2003 The competing risks of death vs. ESRD in Medicare beneficiaries 65+ with chronic kidney disease, CHF and anemia. Am Soc Nephrol, November 1-4, Philadelphia, PA 2002, Abstract SA-P0848
12. Hsu CY, McCulloch CE, Curhan GC 2002 Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13: 504-510
13. Klang B, Bjorvell H, Clyne N 1996 Quality of life in predialytic uremic patients. Qual Life Res 5: 109-116
14. Kausz AT, Obrador GT, Pereira BJG 2000 Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 36: S39-S51
15. Levin A 2001 Prevalence of cardiovascular damage in early renal disease. Nephrol Dial Transplant 16: 7-11
16. Levin A, Singer J, Thompson CR, Ross H, Lewis M 1996 Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27: 347-354
17. Locatelli F, Olivares d, Walker R et al for the European/Australian NESP 980202 Study Group 2001 Novel erythropoiesis-stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60: 741-747
18. London G 2001 Pathophysiology of cardiovascular damage in the early renal population. Nephrol Dial Transplant 16: 3-6
19. Macdougall IC 2000 Novel erythropoiesis-stimulating protein. Semin Nephrol 20: 375-381
20. Mann JF 1994 What are the short-term and long-term consequences of anemia in CRF patients? Nephrol Dial Transplant 14: 29-36
21. National Kidney Foundation 2004 K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm, accessed 21 September 2004
22. Nissenson AR, Swan SK, Lindberg JS et al 2002 Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40: 110-118
23. Obrador GT, Roberts T, St Peter WL, Frazier E, Pereira BJG, Collins AJ 2001 Trends in anemia at initiation of dialysis in the United States. Kidney Int 60: 1875-1884
24. Pereira BJG 2000 Optimization of pre-ESRD care: the key to improved dialysis outcomes. Kidney Int 57: 351-365
25. Portoles J, Torralbo A, Martin P et al 1997 Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29: 541-548
26. Provenzano R, Bhaduri S, Tang L, Klauser M, Singh A 2004a Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease. Final results from the PROMPT study. J Am Soc Nephrol 15: 544A
27. Provenzano R, Garcia-Mayol L, Suchinda P et al 2004b Once-weekly epoetin alfa for treating anemia of chronic kidney disease. Clin Nephrol 61: 392-405
28. Silverberg D, Wexler D, Blum M et al 2003 The correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18: 141-146
29. Suryani MG, Lindberg JS, Navarro J, Elias C, Brenner RM, Walker R 2003 Treatment of anemia with darbepoetin alfa administered de novo every other week in chronic kidney disease. Am J Kidney Dis 23: 106-111
30. Walters BA, Hays RD, Spritzer KL, Fridman M, Carter WB 2002 Health-related quality of life, depressive symptoms, anemia and malnutrition at hemodialysis initiation. Am J Kidney Dis 40: 1185-1194
31. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure 1999 European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 14: 1-50